Publication: 56

Publication: 56

Phase II Trials of Single Agent Anti-VEGF Therapy for Patients with Chronic Lymphocytic Leukemia (CLL)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Leuk Lymphoma vol 51 (12) 2222-2229

Year:: 2010
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:: N01CM62205, N01-CM62207, N01 CM062205, U24 CA114740, CA113408, N01-CM62205, CA114740, P30 CA015083, CA25224, N01CM62207, CA116237, K23 CA113408, U10 CA025224, N01 CM062207, R01 CA116237, N01 CA015083

Corr. Author:
Authors:: Tait Shanafelt Clive Zent John Byrd Charles Erlichman Betsy LaPlant Asish Ghosh Timothy Call Miguel Villalona-Calero Diane Jelinek Deborah Bowen Kristina Laumann Wenting Wu Curtis Hanson Neil Kay

Networks:

Study
Multiple Studies, or Legacy Studies in Alliance Study:: NCCTG-N048F, NCCTG-N0683
Phases:: 2

Keywords:: chronic lymphocytic leukemia, angiogenesis, vascular endothelial growth factor (VEGF), therapy, bevacizumab, receptor tyrosine kinase inhibitor